KA
Kerrisdale Advisers’s Charles River Laboratories CRL Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $1.13M | Sell |
7,458
-2,606
| -26% | -$395K | 0.59% | 35 |
|
|
2025
Q1 | $1.51M | Buy |
10,064
+1,399
| +16% | +$211K | 0.63% | 32 |
|
|
2024
Q4 | $1.6M | Buy |
8,665
+2,160
| +33% | +$399K | 0.54% | 40 |
|
|
2024
Q3 | $1.28M | Sell |
6,505
-3,275
| -33% | -$645K | 0.44% | 52 |
|
|
2024
Q2 | $2.02M | Sell |
9,780
-1,225
| -11% | -$253K | 0.63% | 41 |
|
|
2024
Q1 | $2.98M | Sell |
11,005
-14,118
| -56% | -$3.83M | 0.94% | 32 |
|
|
2023
Q4 | $5.94M | Buy |
25,123
+3,627
| +17% | +$857K | 1.77% | 20 |
|
|
2023
Q3 | $4.21M | Buy |
21,496
+16,952
| +373% | +$3.32M | 1.33% | 25 |
|
|
2023
Q2 | $955K | Buy |
+4,544
| New | +$955K | 0.26% | 66 |
|
|
2022
Q3 | – | Sell |
-7,450
| Closed | -$1.59M | – | 80 |
|
|
2022
Q2 | $1.59M | Sell |
7,450
-6,536
| -47% | -$1.4M | 0.5% | 49 |
|
|
2022
Q1 | $3.97M | Sell |
13,986
-60,281
| -81% | -$17.1M | 1.21% | 21 |
|
|
2021
Q4 | $28M | Buy |
74,267
+39,752
| +115% | +$15M | 5.78% | 7 |
|
|
2021
Q3 | $14.2M | Sell |
34,515
-23,939
| -41% | -$9.88M | 1.54% | 27 |
|
|
2021
Q2 | $21.6M | Sell |
58,454
-64,691
| -53% | -$23.9M | 1.94% | 24 |
|
|
2021
Q1 | $35.7M | Sell |
123,145
-56,503
| -31% | -$16.4M | 2.74% | 14 |
|
|
2020
Q4 | $44.9M | Sell |
179,648
-44,189
| -20% | -$11M | 3.48% | 9 |
|
|
2020
Q3 | $50.7M | Sell |
223,837
-28,754
| -11% | -$6.51M | 3.8% | 2 |
|
|
2020
Q2 | $44M | Buy |
252,591
+3,295
| +1% | +$574K | 4.95% | 3 |
|
|
2020
Q1 | $31.5M | Buy |
249,296
+110,796
| +80% | +$14M | 6.02% | 3 |
|
|
2019
Q4 | $21.2M | Buy |
+138,500
| New | +$21.2M | 7.48% | 4 |
|